Skip to main content
. 2018 Jun 14;9(14):2466–2471. doi: 10.7150/jca.25061

Table 1.

Clinical characteristics of advanced urothelial carcinoma patients grouped by PNI

All (n, %) PNI < 40 (%) PNI ≥ 40 (%) P value
Age (year) 0.81
< 65 74 (52.5) 22 (29.7) 52 (70.3)
≥ 65 67 (47.5) 18 (27.9) 49 (73.1)
Gender 0.34
Female 51 (36.2) 12 (23.5) 39 (76.5)
Male 90 (63.8) 29 (32.2) 61 (67.8)
ECOG 0.40
0-1 104 (73.8) 28 (26.9) 76 (73.1)
≥ 2 37 (26.2) 13 (35.1) 24 (64.9)
Renal function (mL/min) 0.58
CCr ≥ 60 62 (44.0) 20 (32.3) 42 (67.7)
CCr < 60 79 (56.0) 21 (26.6) 58 (73.4)
Primary site 0.85
Upper tract 82 (58.2) 25 (30.5) 57 (69.5)
Bladder 54 (38.3) 15 (27.8) 39 (72.2)
Multifocal 5 (3.5) 1 (20) 4 (80)
Histopathologic variant 0.26
No 89 (63.1) 29 (32.6) 60 (67.4)
Yes 52 (36.9) 12 (23.1) 40 (76.9)
Visceral metastasis 0.009
No 67 (47.5) 12 (17.9) 55 (82.1)
Yes 74 (52.5) 29 (39.2) 45 (60.8)
Liver metastasis 0.054
No 115 (81.6) 29 (25.2) 86 (74.8)
Yes 26 (18.4) 12 (46.2) 14 (53.8)
Lung metastasis 0.16
No 96 (68.1) 24 (25.0) 72 (75.0)
Yes 45 (31.9) 17 (37.8) 28 (62.2)
Bone metastasis 0.09
No 116 (82.3) 30 (25.9) 86 (74.1)
Yes 25 (17.7) 11 (44.0) 14 (56.0)
WBC (× 103/μL) 0.005
< 10 97 (68.8) 21 (21.6) 76 (78.4)
≥ 10 44 (31.2) 20 (45.5) 24 (54.5)
NLR < 0.0001
< 3 55 (39.0) 3 (5.5) 52 (94.5)
≥ 3 86 (61.0) 38 (44.2) 48 (55.8)
Hemoglobin (g/dL) < 0.0001
≥ 10 103 (73.0) 18 (17.5) 85 (82.5)
< 10 38 (27.0) 23 (60.5) 15 (39.5)
First-line chemotherapy 0.35
Cisplatin-based 92 (65.2) 26 (28.3) 66 (71.7)
Carboplatin-based 36 (25.5) 13 (36.1) 23 (63.9)
Other 13 (9.2) 2 (15.4) 11 (84.6)

Abbreviation: CCr, clearance of creatinine; ECOG, Eastern Cooperative Oncology Group; PNI, prognostic nutritional index; NLR, neutrophil to lymphocyte ratio; WBC, white blood cell count